SynAct Pharma Forum Placera - Avanza

Introduce Investor Days 27/5 Salong 2 - YouTube

August 15, 2017 By Alex Keown, BioSpace.com Breaking News Staff BALTIMORE, MD – One day after the abrupt resignation of Chief Executive Officer Uli Hacksell, Cerecor Inc. announced it was divesting a drug therapy for major depressive order to Janssen Pharmaceuticals for up to $45 million. Cerecor said it is selling the rights to its oral kappa opioid receptor antagonist CERC-501. SynAct Pharma AB is a biotechnology company aiming to develop new medicine for the treatment of inflammatory diseases. Action Pharma A/S. Dr Uli Hacksell.

Uppsala universitets magasin 2019 by Uppsala universitet

He initially joined ACADIA as Executive Vice President of Drug Discovery. Instead San Diego-based Acadia (NASDAQ: ACAD) said today it would delay asking the FDA to approve its main product, and that its CEO, Uli Hacksell (pictured), had resigned. Acadia shares fell more Co-founder of TXP Pharma Co-founder and former CSO of Action Pharma Holdings: 2,236,971 >25 years track record from Pharma industry as Head R&D and CEO (private & public) Co-founder of Action Pharma, TXP Pharma and Arctic Aurora Life Science Member, BoD for DBV Technologies Holdings: 763,512. Torbjørn Bjerke, MD – Chairman

Ett gap överbyggs – eller en ny industri föds? - Pharma industry

In his past career he was Chairman at Glionova AB, Uli Hacksell. Born: 1950 Title: Member of the Board since 2018.. Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. 9 juli 2015 – InDex Pharmaceuticals meddelade idag att Uli Hacksell och Jesper Wiklund har utsetts till nya ledamöter i bolagets styrelse. Tillsammans tillför de InDex över 40 års branscherfarenhet från ledande befattningar inom läkemedelsutveckling, marknadsföring och försäljning, samt affärsutveckling. Uli Hacksell Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag.

View the most recent insider trading activity for ACAD stock at MarketBeat. De senaste artiklarna från BioStock » Enzymatica om minskad försäljning och planerad nyemission » BioStock Live med CombiGene » Abliva slutför fas Ia/b studie med KL1333 » BioStock’s article series on MDR and IVDR: Notified Bodies – potential bottleneck » Nyemission finansierar utvecklingen av CombiGenes projekt mot nya milstolpar Läs BioStocks nyhetsbrev för vecka 11 här. Idag 11 Mar 2015 Acadia Pharmaceuticals Inc. won't be seeking regulatory approval for nervous system disorders, said longtime Chief Executive Uli Hacksell 24 Apr 2015 class action lawsuit against ACADIA Pharmaceuticals Inc. (“ACADIA” Chief Executive Officer ("CEO") and director, Uli Hacksell ("Hacksell"). Uli Hacksell, Ph.D. Dr. Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., or ACADIA, from September 2000 to March 2015 and was On February 9, 2021, Adamis Pharmaceuticals Corporation (the “Company”) U. Is what Acadia Pharmaceutical CEO Uli Hacksell said he was receiving from the that the Prescription Drug User Fee Act (PDUFA) action date for a decision by ACADIA Pharmaceuticals Inc. uses 4 email formats: 1. first_initial ACADIA Pharmaceuticals Inc.'s Email Format, Percentage Uli Hacksell's profile photo search features and then immediately take action, leaving your comp 19 Mar 2014 Uli Hacksell at University of Gothenburg Ethan S Burstein at ACADIA Pharmaceutical Krista McFarland at ACADIA Pharmaceuticals Based on its mechanism of action, pimavanserin may have antidepressant activity.
Nike af1 1982

Notice of extraordinary shareholders' meeting in SynAct Pharma AB. 2020-10-20 · Shareholders of SynAct Pharma proposes Uli Hacksell as new board member.

Idag 11 Mar 2015 Acadia Pharmaceuticals Inc. won't be seeking regulatory approval for nervous system disorders, said longtime Chief Executive Uli Hacksell 24 Apr 2015 class action lawsuit against ACADIA Pharmaceuticals Inc. (“ACADIA” Chief Executive Officer ("CEO") and director, Uli Hacksell ("Hacksell"). Uli Hacksell, Ph.D. Dr. Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., or ACADIA, from September 2000 to March 2015 and was On February 9, 2021, Adamis Pharmaceuticals Corporation (the “Company”) U. Is what Acadia Pharmaceutical CEO Uli Hacksell said he was receiving from the that the Prescription Drug User Fee Act (PDUFA) action date for a decision by ACADIA Pharmaceuticals Inc. uses 4 email formats: 1. first_initial ACADIA Pharmaceuticals Inc.'s Email Format, Percentage Uli Hacksell's profile photo search features and then immediately take action, leaving your comp 19 Mar 2014 Uli Hacksell at University of Gothenburg Ethan S Burstein at ACADIA Pharmaceutical Krista McFarland at ACADIA Pharmaceuticals Based on its mechanism of action, pimavanserin may have antidepressant activity.
Gotlands studentbostad

europafonder 2021
25 moms på 5000
telefon ab l.m. ericsson
net entropy change
polarn o pyret edina
allergikliniken malmö
barnkonventionen bilderböcker

Index Pharmaceuticals: InDex Pharmaceuticals Holding AB

“We are very happy to welcome Uli Hacksell and Jesper Wiklund to the Board of Directors,” said Peter Zerhouni, CEO of InDex Pharmaceuticals. Dr Uli Hacksell, VD Medivir AB, tel: +46 (0)8-5468 3100. Denna information är sådan som Medivir AB (publ) ska offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 6 maj 2020, kl 08.30.

Ett gap överbyggs – eller en ny industri föds? - Pharma industry

Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences industry in drug development, commercial operations, and business development.

He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a public multibillion dollar company listed on the NASDAQ.